- Home
- DBVT vs ITIC Comparison
DBVT vs ITIC Comparison
Compare DBVT & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- ITIC
- Stock Information
- Founded
- DBVT 2002
- ITIC 1972
- Country
- DBVT France
- ITIC United States
- Employees
- DBVT N/A
- ITIC N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- ITIC Specialty Insurers
- Sector
- DBVT Health Care
- ITIC Finance
- Exchange
- DBVT Nasdaq
- ITIC Nasdaq
- Market Cap
- DBVT 464.0M
- ITIC 517.1M
- IPO Year
- DBVT N/A
- ITIC N/A
- Fundamental
- Price
- DBVT $15.55
- ITIC $261.42
- Analyst Decision
- DBVT Buy
- ITIC
- Analyst Count
- DBVT 4
- ITIC 0
- Target Price
- DBVT $14.81
- ITIC N/A
- AVG Volume (30 Days)
- DBVT 203.8K
- ITIC 33.5K
- Earning Date
- DBVT 10-28-2025
- ITIC 11-03-2025
- Dividend Yield
- DBVT N/A
- ITIC 5.98%
- EPS Growth
- DBVT N/A
- ITIC 25.49
- EPS
- DBVT N/A
- ITIC 17.49
- Revenue
- DBVT $3,800,000.00
- ITIC $269,460,000.00
- Revenue This Year
- DBVT $1,743.46
- ITIC N/A
- Revenue Next Year
- DBVT $1,044.34
- ITIC N/A
- P/E Ratio
- DBVT N/A
- ITIC $14.95
- Revenue Growth
- DBVT N/A
- ITIC 15.27
- 52 Week Low
- DBVT $2.21
- ITIC $190.20
- 52 Week High
- DBVT $18.00
- ITIC $290.40
- Technical
- Relative Strength Index (RSI)
- DBVT 60.41
- ITIC 51.54
- Support Level
- DBVT $14.85
- ITIC $259.05
- Resistance Level
- DBVT $16.95
- ITIC $269.64
- Average True Range (ATR)
- DBVT 1.14
- ITIC 6.15
- MACD
- DBVT -0.18
- ITIC -0.57
- Stochastic Oscillator
- DBVT 28.24
- ITIC 58.39
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.